January 2024 Br J Cardiol 2024;31:23–6 doi:10.5837/bjc.2024.003
Charlotte Gross, Hiba Hammad, Thomas A Slater, Sam Straw, Thomas Anderton, Caroline Coyle, Melanie McGinlay, John Gierula, V Kate Gatenby, Vikrant Nayar, Jiv N Gosai, Klaus K Witte
Abstract
Introduction
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve symptoms,1 reduce hospitalisations and extend longevity2,3 for patients who have heart failure with reduced ejection fraction (HFrEF). These beneficial effects are observed very early following initiation,4 prompting calls for these agents to be given equal priority to more established therapies,5,6 which has been reflected in recent guidelines.7 Hospitalisation with heart failure (HF) offers the opportunity for optimisation of guideline-directed medical therapy (GDMT) including SGLT2i,8,9 however, the feasibility of doing so has not been reported outside of the artifici
|
Full text
